Differential Thyroid Cancer In Multinodular Goiter; Review Of 96 Cases Differential Thyroid Cancer In Multinodular Goiter
Article Sidebar
Main Article Content
Abstract
Abstract
The global prevalence of multinodular goiter is high, with most cases occurring in developing countries. Previously published literature revealed that the incidence of differentiated thyroid carcinoma among patients with multinodular goiter has risen. This study aims to determine the frequency of differentiated thyroid cancer in multinodular goiter patients. This cross-sectional study was done among 96 patients with multinodular goiter admitted to the surgical ward in Imam Hussein Teaching Hospital/ AL-Nasiriyah-Iraq from 1 February 2021 to 31 January 2022. The mean age was 39.4 years old. Females were predominant 79/96 (82.3 %). 32% of the multinodular goiter patients had differentiated thyroid carcinoma by histopathology, while it was 21% by fine needle aspiration. The histopathology of multinodular goiter patients revealed that 67.7% had endemic goiter, 19.8% had papillary carcinoma, and 9.4% had Follicular thyroid carcinoma. Smoking and older age were both significantly associated with differentiated thyroid carcinoma in patients with multinodular goiter. In conclusion, with a high proportion of malignancy among multinodular thyroid goiter participants by FNA and histopathology, acceptable needle aspiration test result was a low-accurate tool for differentiated thyroid carcinoma diagnosis.
Keywords: AL-Nasiriyah, Differentiated thyroid cancer, Imam Hussein Teaching Hospital, MNG.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/